FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 02-742-N (400/141)	<b>Serial No.</b> 10/758,155
	(Use several sheets if necessary)		
		Applicant: McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	1635

## **U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
/AB/	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US 2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
	*	US-2003/0216335	11/27/02	Lockridge et al.			11/20/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2004/0161844	11/04/03	Baker et al.			08/19/04
	*	US-2004/0209832	09/23/03	McSwiggen et al.			10/21/04
	*	US-2005/0020521	09/25/05	Rana, Tariq M.			01/27/05
	*	US-2005/0171039	05/11/04	McSwiggen et al.			08/04/05
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
V	*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

EXAMINER /Amy Bowman/	DATE CONSIDERED	07/12/2007

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
	SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	02-742-N (400/141)	10/758,155
		Applicant: McSwiggen et al.	
<u> </u>		Filing Date:	Group:
		January 12, 2004	1635

## **U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/AB/	*	5,587,471	12/24/96	Cook et al.			
	*	5,814,620	09/29/98	Robinson et al.			
	*	5,916,763	06/29/99	Williams et al.			
	*	5,998,148	12/07/99	Bennett et al.			
	*	5,998,206	12/07/99	Cowsert			
	*	6,060,456	05/09/00	Arnold et al.			
	*	6,214,805	04/10/01	Torrence et al.			
	*	6,506,559	01/14/03	Fire et al.			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,710,174	03/23/04	Bennett et al.			
	*	6,824,972	11/30/04	Kenwrick et al.			
	*	7,022,828	04/04/06	McSwiggen et al.			
V	*	7,078,196	07/18/06	Tuschl et al.			

EXAMINER	/Amy Bowman/	DATE CONSIDERED	07/12/2007
<u>L</u>			

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
	SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	02-742-N (400/141)	10/758,155
		Applicant: McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	1635

## **FOREIGN PATENT DOCUMENTS**

			Document Number	Date	Country	Class	Subclas s	Trans	lation
							ļ	Yes	No
/AB	3/*		1389637	08/05/02	EP (Klippel et al.)				
	*	•	90/14090	11/29/90	WO (Gillespie et al.)				
	*	r	97/21808	06/19/97	WO (Robinson)				
	*		01/97850	12/27/01	WO (Siemeister et al.)				,
	*	,	03/044188	05/30/03	WO (Tei et al.)				
	*	•	04/029212	04/08/04	WO (Rana, Tariq M.)				
	*	•	04/043977	05/27/04	WO (Prakush et al.)				
	*	•	04/072261	08/26/04	WO (Li et al.)				
V	*		04/090105	10/21/04	WO (Leake et al.)				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

/AB/ *	Alexeev et al., "Localized in vivo genotypic and phentypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
/AB/ *	Bellon et al., "4-Thio-oligo-β-D-ribonucleotides: synthesis of β-4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)

EXAMINER	/Amy Bowman/	DATE CONSIDERED	07/12/2007

Sheet 4 of 5

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
	SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	02-742-N (400/141)	10/758,155
	,	Applicant: McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	1635

/A <b>I</b>	ιB/	*	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (2001)
		*	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
		*	Braasch et al., "RNA Inteference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
		*	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," Science, 309, 1529-1530 (2005)
		*	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
		*	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," FEBS Letters, 543:51-54 (2003)
		*	Hammond et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," Nature, 2:110-119 (2001)
		*	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
		*	Hornung et al., "Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
		*	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
		*	Kawaski et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," J. Med. Chem., 36, 831-841 (1993)
		*	Mattick, John S., "The Functional Genomics of Noncoding RNA", Science, 309, 1527-1528 (2005)
		*	McCaffrey et al., "RNA interference in adult mice," Nature, 148, 38-39 (2002)
		*	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <u>J. Biol. Chem</u> . 268:14514-14522 (1993)
1	/	*	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)

		- Contraction Cont			
EXAMINER	/Amy Bowman/		DATE CONSIDERED	07/12/2007	

Sheet 5 of 5

FORM PTO-1449	U.S. Department of Commerce	Atty. Docket No.	Serial No.
(Rev. 2-32)	Patent and Trademark Office  SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	02-742-N (400/141)	10/758,155
		Applicant: McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	1635

/AB/	*	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
/AB/	*	Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
/AB/	*	Pavco et al., "Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors," Clinical Cancer Research 6:2094-2103 (2000)
/AB/	*	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <u>Nucleic Acids Research</u> 21:5600-5603 (1993)

F				
EXAMINER	/Amy Bowman/	DA	ATE CONSIDERED	07/12/2007